Bharat Parenterals (NSE:BPLPHARMA) Cyclically Adjusted Revenue per Share: ₹0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:BPLPHARMA Bharat Parenterals Ltd NSE:BPLPHARMA
55 GF Score
Price ₹1,294.70
GF Value ₹1,232.25
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Bharat Parenterals Cyclically Adjusted Revenue per Share?

Bharat Parenterals NSE:BPLPHARMA +1.60% 55 Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus rates NSE:BPLPHARMA with a GF Score™ of 55/100 and a GF Value™ of ₹1,232.25 (Fairly Valued). The stock has 5 warning signs investors should review.

Note: As Cyclically Adjusted Revenue per Share is a main component used to calculate Cyclically Adjusted PS Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation section below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Bharat Parenterals's adjusted revenue per share for the three months ended in Jun. 2026 was ₹136.008. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is ₹0.00 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Bharat Parenterals's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-21), Bharat Parenterals's current stock price is ₹1294.70. Bharat Parenterals's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was ₹0.00. Bharat Parenterals's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bharat Parenterals was 4.33. The lowest was 2.05. And the median was 2.82.


Bharat Parenterals  (NSE:BPLPHARMA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Bharat Parenterals was 4.33. The lowest was 2.05. And the median was 2.82.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Bharat Parenterals Cyclically Adjusted Revenue per Share Related Terms


Bharat Parenterals Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Bharat Parenterals's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Parenterals Cyclically Adjusted Revenue per Share Chart

Bharat Parenterals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bharat Parenterals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:BPLPHARMA vs : Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bharat Parenterals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bharat Parenterals Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bharat Parenterals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Bharat Parenterals's Cyclically Adjusted PS Ratio falls into.


NSE:BPLPHARMA
55GF Score
Bharat Parenterals Ltd NSE:BPLPHARMA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bharat Parenterals Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Bharat Parenterals's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=136.008/333.9520*333.9520
=136.008

Current CPI (Jun. 2026) = 333.9520.

Bharat Parenterals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 46.669 241.428 64.554
201612 47.188 241.432 65.271
201703 57.851 243.801 79.243
201706 47.319 244.955 64.511
201709 64.631 246.819 87.447
201712 56.276 246.524 76.234
201803 70.086 249.554 93.789
201806 64.921 251.989 86.037
201809 88.304 252.439 116.818
201812 156.193 251.233 207.620
201903 73.134 254.202 96.078
201906 86.579 256.143 112.879
201909 86.815 256.759 112.915
201912 129.428 256.974 168.199
202003 95.560 258.115 123.637
202006 95.745 257.797 124.029
202009 103.998 260.280 133.435
202012 86.475 260.474 110.869
202103 70.402 264.877 88.762
202106 106.178 271.696 130.507
202109 105.447 274.310 128.374
202112 66.586 278.802 79.757
202203 90.596 287.504 105.232
202206 45.264 296.311 51.014
202209 141.916 296.808 159.676
202212 102.305 296.797 115.112
202303 87.507 301.836 96.818
202306 121.140 305.109 132.592
202309 101.943 307.789 110.608
202312 94.952 306.746 103.374
202403 109.109 312.332 116.662
202406 141.800 314.175 150.726
202409 109.795 315.301 116.290
202412 132.934 315.605 140.662
202503 150.868 319.799 157.545
202506 168.310 322.561 174.254
202509 124.966 324.800 128.487
202512 94.585 324.054 97.474
202603 144.550 330.213 146.187
202606 136.008 333.952 136.008

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of ₹0.00 mean?
Bharat Parenterals (NSE:BPLPHARMA) has a Cyclically Adjusted Revenue per Share of ₹0.00 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bharat Parenterals and its competitors.
Is Bharat Parenterals' Cyclically Adjusted Revenue per Share too high?
Bharat Parenterals' current Cyclically Adjusted Revenue per Share is ₹0.00. Overall, Bharat Parenterals has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Bharat Parenterals' Cyclically Adjusted Revenue per Share compare to ?
Bharat Parenterals' Cyclically Adjusted Revenue per Share of ₹0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Bharat Parenterals and its competitors. Bharat Parenterals's current Cyclically Adjusted Revenue per Share is ₹0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Parenterals stock overvalued right now?
Based on GuruFocus' analysis, Bharat Parenterals (NSE:BPLPHARMA) is currently considered Fairly Valued. The stock's GF Value™ is ₹1,232.25, compared to a current price of ₹1,294.70 — trading 5.1% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is ₹0.00. Bharat Parenterals' overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Bharat Parenterals (NSE:BPLPHARMA), the current Cyclically Adjusted Revenue per Share is ₹0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bharat Parenterals (NSE:BPLPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Bharat Parenterals stock appears to be overvalued. The current stock price of ₹1,294.70 is trading 5.1% above its estimated GF Value™ of ₹1,232.25. GuruFocus considers Bharat Parenterals to be Fairly Valued.

Key valuation signals for NSE:BPLPHARMA:

  • Cyclically Adjusted Revenue per Share: ₹0.00
  • GF Value™: ₹1,232.25 vs. price of ₹1,294.70 (5.1% above fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the NSE:BPLPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bharat Parenterals Business Description

Comparable Companies
Other Exchanges 541096:India
Address Survey No.144-A, Jarod Samlaya Road, Village Haripura, Tehsil Savli, Vadodara, GJ, IND, 391520
Bharat Parenterals Ltd is a pharmaceutical company. It provides various products such as Capsules, Dry Syrups, Sachets, Oral Liquids, Injections, Semisolids, and others. Geographically, the group has a business presence in India and Outside India.
55GF Score

Get the complete analysis for NSE:BPLPHARMA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,294.70
Price
₹1,232.25
GF Value